Elekta's Nucletron division has received clearance from the U.S. Food and Drug Administration (FDA) for its Esteya electronic brachytherapy system.
The system is designed for treating skin cancer, according to Nucletron. It applies radiation directly to the cancer site, allowing physicians to focus more therapeutic radiation on the disease target and to minimize radiation to surrounding tissues and organs.
The first installations of Esteya in the U.S. are scheduled to occur in the next few months, Nucletron said.
